141 related articles for article (PubMed ID: 2448025)
1. Prognostic factors in medullary thyroid carcinomas. Survival in relation to age, sex, stage, histology, immunocytochemistry, and DNA content.
Schröder S; Böcker W; Baisch H; Bürk CG; Arps H; Meiners I; Kastendieck H; Heitz PU; Klöppel G
Cancer; 1988 Feb; 61(4):806-16. PubMed ID: 2448025
[TBL] [Abstract][Full Text] [Related]
2. Chromogranin A: an additional tumor marker for postoperative recurrence and metastases of medullary thyroid carcinomas?
Franke WG; Pinkert J; Runge R; Bredow J; Wunderlich G; Koch R
Anticancer Res; 2000; 20(6D):5257-60. PubMed ID: 11326706
[TBL] [Abstract][Full Text] [Related]
3. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables.
Dottorini ME; Assi A; Sironi M; Sangalli G; Spreafico G; Colombo L
Cancer; 1996 Apr; 77(8):1556-65. PubMed ID: 8608543
[TBL] [Abstract][Full Text] [Related]
4. Lymph node metastases and elevated postoperative calcitonin: Predictors of poor survival in medullary thyroid carcinoma.
Siironen P; Hagström J; Mäenpää HO; Louhimo J; Arola J; Haglund C
Acta Oncol; 2016; 55(3):357-64. PubMed ID: 26339947
[TBL] [Abstract][Full Text] [Related]
5. Prognostic variables and calcitonin in medullary thyroid cancer.
Clark JR; Fridman TR; Odell MJ; Brierley J; Walfish PG; Freeman JL
Laryngoscope; 2005 Aug; 115(8):1445-50. PubMed ID: 16094121
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of calcitonin immunoreactivity, amyloid staining, and flow cytometric DNA measurements in medullary thyroid carcinoma.
Pyke CM; Hay ID; Goellner JR; Bergstralh EJ; van Heerden JA; Grant CS
Surgery; 1991 Dec; 110(6):964-70; discussion 970-1. PubMed ID: 1745984
[TBL] [Abstract][Full Text] [Related]
7. Reduced Retinoblastoma Protein Expression Is Associated with Decreased Patient Survival in Medullary Thyroid Cancer.
Valenciaga A; Grubbs EG; Porter K; Wakely PE; Williams MD; Cote GJ; Vasko VV; Saji M; Ringel MD
Thyroid; 2017 Dec; 27(12):1523-1533. PubMed ID: 29105562
[TBL] [Abstract][Full Text] [Related]
8. Cytophotometric DNA measurements in medullary thyroid carcinoma.
Galera-Davidson H; González-Cámpora R; Mora-Marín JA; Matilla-Vincente A; Dytch HE; Bartels PH; Lerma-Puertas E; Andrada-Becerra E; Bibbo M
Cancer; 1990 May; 65(10):2255-60. PubMed ID: 2346910
[TBL] [Abstract][Full Text] [Related]
9. Medullary carcinoma of the thyroid gland: an immunocytochemical study.
Holm R; Sobrinho-Simões M; Nesland JM; Gould VE; Johannessen JV
Ultrastruct Pathol; 1985; 8(1):25-41. PubMed ID: 3901454
[TBL] [Abstract][Full Text] [Related]
10. Medullary thyroid carcinoma: clinical features and long-term follow-up of seventy-eight patients treated between 1969 and 1986.
Girelli ME; Nacamulli D; Pelizzo MR; De Vido D; Mian C; Piccolo M; Busnardo B
Thyroid; 1998 Jun; 8(6):517-23. PubMed ID: 9669290
[TBL] [Abstract][Full Text] [Related]
11. Surgical strategy for the treatment of sporadic medullary thyroid carcinoma: our experience.
Lupone G; Antonino A; Rosato A; Zenone P; Iervolino EM; Grillo M; De Palma M
G Chir; 2012; 33(11-12):395-9. PubMed ID: 23140924
[TBL] [Abstract][Full Text] [Related]
12. Expression of Prox1 in Medullary Thyroid Carcinoma Is Associated with Chromogranin A and Calcitonin Expression and with Ki67 Proliferative Index, but Not with Prognosis.
Saglietti C; La Rosa S; Sykiotis GP; Letovanec I; Bulliard JL; Piana S; Mermod M; Petrova T; Uccella S; Sessa F; Bongiovanni M
Endocr Pathol; 2019 Jun; 30(2):138-145. PubMed ID: 31001799
[TBL] [Abstract][Full Text] [Related]
13. Medullary carcinoma of the thyroid. An immunocytochemical and histochemical study of 25 cases using eight separate markers.
Sikri KL; Varndell IM; Hamid QA; Wilson BS; Kameya T; Ponder BA; Lloyd RV; Bloom SR; Polak JM
Cancer; 1985 Nov; 56(10):2481-91. PubMed ID: 2412687
[TBL] [Abstract][Full Text] [Related]
14. Histopathologic characteristics and nuclear DNA content as prognostic factors in medullary thyroid carcinoma. A nationwide study in Sweden. The Swedish MTC Study Group.
Bergholm U; Adami HO; Auer G; Bergström R; Bäckdahl M; Grimelius L; Hansson G; Ljungberg O; Wilander E
Cancer; 1989 Jul; 64(1):135-42. PubMed ID: 2731109
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic and DNA cytometric analysis of carcinoid tumors of the thymus.
Goto K; Kodama T; Matsuno Y; Yokose T; Asamura H; Kamiya N; Shimosato Y
Mod Pathol; 2001 Oct; 14(10):985-94. PubMed ID: 11598168
[TBL] [Abstract][Full Text] [Related]
16. The variable pathologic presentations of medullary and micro-medullary thyroid carcinoma: an institutional experience.
Samulski TD; Livolsi VA; Montone K; Baloch Z
Pathol Res Pract; 2014 Mar; 210(3):182-5. PubMed ID: 24440099
[TBL] [Abstract][Full Text] [Related]
17. Regulatory peptides and other neuroendocrine markers in medullary carcinoma of the thyroid.
Hanna FW; Ardill JE; Johnston CF; Cunningham RT; Curry WJ; Russell CF; Buchanan KD
J Endocrinol; 1997 Feb; 152(2):275-81. PubMed ID: 9071985
[TBL] [Abstract][Full Text] [Related]
18. Medullary thyroid carcinoma experienced at Kanazawa University Hospital.
Mizukami Y; Nonomura A; Michigishi T; Noguchi M; Ohtake S; Nakamura S; Ishizaki T
J Surg Oncol; 1996 Jan; 61(1):27-33. PubMed ID: 8544456
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical hormone content in medullary and undifferentiated thyroid carcinoma and prognosis after surgery.
Henninger S; Schatz H; Stracke H; Wagner U; Kracht J
Acta Histochem; 1988; 83(1):51-6. PubMed ID: 2897752
[TBL] [Abstract][Full Text] [Related]
20. Medullary thyroid cancer. An immunohistochemical and humoral study using six separate antigens.
Pacini F; Basolo F; Elisei R; Fugazzola L; Cola A; Pinchera A
Am J Clin Pathol; 1991 Mar; 95(3):300-8. PubMed ID: 1996540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
